Literature DB >> 31909480

Update on the use of dapsone in dermatology.

Nohra Ghaoui1, Edith Hanna2, Ossama Abbas3, Abdul-Ghani Kibbi3, Mazen Kurban3,4.   

Abstract

Dapsone (4,4'-diaminodiphenylsulfone) is the only remaining sulfone used in anthropoid therapeutics and is commercially available as an oral formulation, an inhaled preparation, and a 5% or 7.5% cream. Dapsone has antimicrobial effects stemming from its sulfonamide-like ability to inhibit the synthesis of dihydrofolic acid. It also has anti-inflammatory properties such as inhibiting the production of reactive oxygen species, reducing the effect of eosinophil peroxidase on mast cells and down-regulating neutrophil-mediated inflammatory responses. This allows for its use in the treatment of a wide variety of inflammatory and infectious skin conditions. Currently in dermatology, the US Food and Drug Administration (FDA)-approved indications for dapsone are leprosy, dermatitis herpetiformis, and acne vulgaris. However, it proved itself as an adjunctive therapeutic agent to many other skin disorders. In this review, we discuss existing evidence on the mechanisms of action of dapsone, its FDA-approved indications, off-label uses, and side effects.
© 2020 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31909480     DOI: 10.1111/ijd.14761

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  10 in total

1.  Dioscin alleviates lipopolysaccharide-induced acute lung injury through suppression of TLR4 signaling pathways.

Authors:  Chuntao Wang; Qingnian Li; Tianyu Li
Journal:  Exp Lung Res       Date:  2020-01-14       Impact factor: 2.459

Review 2.  A comprehensive insight into the anti-inflammatory properties of dapsone.

Authors:  Mina Khalilzadeh; Maryam Shayan; Sina Jourian; Mohammad Rahimi; Mohammad Sheibani; Ahmad Reza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-20       Impact factor: 3.195

3.  MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.

Authors:  Richard E Kast; Alex Alfieri; Hazem I Assi; Terry C Burns; Ashraf M Elyamany; Maria Gonzalez-Cao; Georg Karpel-Massler; Christine Marosi; Michael E Salacz; Iacopo Sardi; Pieter Van Vlierberghe; Mohamed S Zaghloul; Marc-Eric Halatsch
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

4.  4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.

Authors:  Jong-Hoon Lee; Ha Kyeu An; Mun-Gi Sohn; Paul Kivela; Sangsuk Oh
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

5.  Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.

Authors:  Richard E Kast
Journal:  Med Sci (Basel)       Date:  2021-02-16

Review 6.  Development of Pigmentation-Regulating Agents by Drug Repositioning.

Authors:  Seo-Mi-Gon Jeong; Tae-Jin Yoon
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

Review 7.  Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.

Authors:  Valerie D Callender; Hilary Baldwin; Fran E Cook-Bolden; Andrew F Alexis; Linda Stein Gold; Eric Guenin
Journal:  Am J Clin Dermatol       Date:  2021-11-09       Impact factor: 7.403

8.  Cardiac Tamponade: A Rare Manifestation of Familial Mediterranean Fever.

Authors:  Abdolreza Malek; Tina Zeraati; Ariane Sadr-Nabavi; Niloofar Vakili; Mohammad Reza Abbaszadegan
Journal:  Case Rep Rheumatol       Date:  2022-02-07

Review 9.  Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.

Authors:  Connor Cole; Keshavamurthy Vinay; Luca Borradori; Kyle T Amber
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

Review 10.  Dapsone, More than an Effective Neuro and Cytoprotective Drug.

Authors:  Araceli Diaz-Ruiz; Juan Nader-Kawachi; Francisco Calderón-Estrella; Alfonso Mata-Bermudez; Laura Alvarez-Mejia; Camilo Ríos
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.